Table 1.
Representative clinical trials of oncolytic viruses with gemcitabine as treatment for pancreatic cancer
| Virus category | Virus names | Study phase |
Structural modification | Chemotherapy intervention | Outcome measures | Clinical Trial ID/reference |
|---|---|---|---|---|---|---|
| oncolytic adenovirus | LOAd703 | I/II | EIACR2 deletion, CD40L and 4-1BBL insertion | yes | Overall Response Rate Overall Survival |
NCT02705196 |
| oncolytic adenovirus | VCN-01 | I | EIACR2 deletion, PH20 hyaluronidase addition | yes | Recommended Phase 2 Dose (RP2D) of VCN-01 | NCT02045589 |
| oncolytic adenovirus | VCN-01 | I | EIACR2 deletion, PH20 hyaluronidase addition | yes | Safety and Tolerability, Presence of VCN-01 in tumor | NCT02045602 |
| oncolytic adenovirus | ONYX-015 | I/II | E1B55K gene deletion | yes | treatment effect | 65 |
| herpesviruses | OrienX010 | I | Recombinant hGM-CSF | no | preliminary efficacy | NCT01935453 |
| herpesviruses | HF10 | I | UL56 deletion | yes | Dose limiting toxicity (DLT) Adverse events (AEs) |
NCT03252808 |
| herpesviruses | HF10 | I | UL56 deletion | yes | safety assessment | 104 |
| herpesviruses | T-VEC | I | ICP34.5 and ICP47 Deletions, GM-CSF Insertion | no | Change in size of injected lesion(s),Overall response rate | NCT03086642 |
| herpesviruses | T-VEC | I | ICP34.5 and ICP47 Deletions, GM-CSF Insertion | no | Adverse Events, (HSV-1) Antibodies | NCT00402025 |
| Vaccinia virus | PANVAC-F plus PANVAC-V | I | None | no | MTD of falimarev. T cell proliferation, Cytokine production | NCT00669734 |
| Vaccinia virus | MVAp53 | I | Express WT murine p53 |
no | Safety and tolerance, Immunogenicity | NCT01191684 |
| Vaccinia virus | p53MVA | I | Express p53 and pembrolizumab | no | Tolerability, | NCT02432963 |
| reoviruses | Reolysin | II | None | yes | clinical benefit rate, safety and tolerability | NCT00998322 |